|
|
|
|
|
|
|
|
| About Alvin Berger (Metabolon) |
|
Dr. Alvin Berger is an authority in the utilization of state of the art “omic’ tools in the fields of lipid research, nutritional biochemistry, and pharmaceutical science. Dr. Berger received his post-doctoral training from Georgetown University/Lombardi Cancer Center (‘93-96), his Ph. D from University of California Davis (‘87-92), M.S from the University of Washington (’84-87), and has written 8 patents; 42 research papers; 23 review articles, numerous book chapters; and one edited book.
At Nestle (Lausanne, Switzerland), Dr. Berger led development of lipid neutraceutical ingredients for oral/topical application. With plant sterols and cholesterol-lowering agents, he managed: research in cells/animals/humans, conducted numerous clinical trials, and developed a commercial milk beverage (Acticol.
At Cytochroma (Toronto, Canada), a company developing inhibitors of P450s which catabolize vitamin D, he directed the Bio-Analytical-, Lipidomic- and Formulation groups. He contributed to: pre-clinical animal research in psoriasis and oncology; and drug development/discovery.
At Icoria, he directed the Metabolomics group, using mass spectrometry to quantify all biochemicals in biological samples. This permits discovery of biomarkers, hidden toxicities, and mechanisms of action, creating safer, more effective, and individually tailored, drugs and foods/consumer products. He was the principal investigator on several grants.
Currently at Metabolon, he directs the Biochemistry program facilitating and expediting interpretation of data. He also leads the scientific development of advanced stream-lined products for Metabolon. In this role, Dr. Berger leads the biochemical analyses and presentation of results with clients. Lastly, he assists Metabolon’s diagnostic efforts in developing disease biomarkers.
Dr. Berger is an Associate Adjunct Professor in Nutrition at The University North Carolina, Chapel Hill since 2004.
|
|
Metabolomics to Advance Drug Discovery
Alvin Berger, Metabolon
Metabolon has developed a metabolomics technology that allows the quantitative measurement and identification of the repertoire of biochemicals contained in a biological sample. The integration of metabolomics data, through its biochemical context with proteomic, transcriptomic and genomic data is one of the aspects that make metabolomics data so useful.
We have used this technology to identify drug mechanism of action (MOA); to find toxicities in marketed drugs and new chemical entities in development, and to identify biomarkers for disease leading to development of new drug targets. The discussion will cover an introduction to the technology of metabolomics and a summary of results from several successful client commercial projects and internal diagnostic projects.
|
|
|
|
|
|
|
|
|
|
|
